NASDAQ · LYEL
Healthcare · Biotechnology
$11.04
Down-$0.16 (-1.45%)
Updated Nov 3, 2026, 1:49 AM
SID Score
3.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · LYEL
1M range · 20 trading sessions · Daily adjusted prices
Prices through Oct 30, 2026
LYEL closed at $11.04 after 20 trading sessions, up 21.72% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 30, 2026 | $11.26 | $11.425 | $10.79 | $11.04 | 113.26K |
| Oct 29, 2026 | $11.00 | $11.62 | $11.00 | $11.305 | 149.22K |
| Oct 28, 2026 | $10.01 | $11.03 | $9.84 | $10.93 | 156.81K |
| Oct 27, 2026 | $9.34 | $10.14 | $9.26 | $10.12 | 127.91K |
| Oct 26, 2026 | $9.35 | $9.42 | $9.075 | $9.31 | 85.22K |
| Oct 23, 2026 | $9.33 | $9.445 | $9.05 | $9.39 | 101.64K |
| Oct 22, 2026 | $9.40 | $9.69 | $9.27 | $9.38 | 93.16K |
| Oct 21, 2026 | $9.65 | $10.12 | $9.29 | $9.41 | 118.32K |
| Oct 20, 2026 | $8.74 | $10.01 | $8.565 | $9.70 | 158.62K |
| Oct 19, 2026 | $8.00 | $9.05 | $7.92 | $8.80 | 212.92K |
| Oct 16, 2026 | $8.24 | $8.44 | $7.9214 | $8.12 | 194.96K |
| Oct 15, 2026 | $8.00 | $8.44 | $7.76 | $8.19 | 324.99K |
| Oct 14, 2026 | $7.42 | $8.285 | $7.195 | $7.99 | 402.24K |
| Oct 13, 2026 | $8.27 | $8.27 | $7.39 | $7.51 | 187.17K |
| Oct 12, 2026 | $8.63 | $8.69 | $8.23 | $8.27 | 100.39K |
| Oct 9, 2026 | $8.72 | $9.10 | $8.615 | $8.71 | 106.81K |
| Oct 8, 2026 | $8.49 | $8.845 | $8.21 | $8.79 | 194.72K |
| Oct 7, 2026 | $8.48 | $8.95 | $8.38 | $8.56 | 184.67K |
| Oct 6, 2026 | $9.13 | $9.13 | $8.585 | $8.61 | 125.04K |
| Oct 5, 2026 | $9.27 | $9.31 | $8.66 | $9.07 | 129.45K |
The latest Smart Investors Daily articles mentioning LYEL.
Company
Market Activity
Research & News
LYEL research
Company profile and research snapshot.
Lyell Immunopharma Inc is a clinical-stage cell therapy company. It has a pipeline of product candidates for patients with solid tumors utilizing ex vivo genetic and epigenetic T-cell reprogramming technologies. The company's product pipeline includes, LYL797, LYL119, LYL845 among others.
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Sep 11, 2026 | Needham | Buy | — |
| Aug 6, 2026 | Stifel | Buy | — |
| Jul 22, 2026 | B. Riley Securities | Buy | — |
| Jun 15, 2026 | Citizens | Market Outperform | — |
| Jun 15, 2026 | Needham | Buy | — |
No generated briefing is available yet.
Yahoo · Oct 13, 2026
Lyell Immunopharma (LYEL) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Yahoo · Sep 14, 2026
SOUTH SAN FRANCISCO, Calif., Sept. 14, 2026 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a late-stage clinical company advancing a pipeline of next-generation chimeric antigen receptor (CAR) T-cell therapies for patients with cancer, today announced that members of its senior management team will participate in the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026, in New York with a fireside chat scheduled for 2:00 pm Eastern Time. A live webcast of the fire
Benzinga · Sep 11, 2026
Needham analyst Gil Blum reiterates Lyell Immunopharma (NASDAQ:LYEL) with a Buy and maintains $44 price target.
Yahoo · Sep 10, 2026
Technology transfer to LyFE Manufacturing Center™ completed following FDA review of improved manufacturing process and updated analytical methodsDosing of additional patients with the new process at LyFE continues with the goal of determining the recommended Phase 2 dose and optimized safety management plan to support End-of-Phase 1 discussions with the FDAAdditional clinical data from the Phase 1/2 trial of LYL273 in patients with third- or later-line relapsed/refractory metastatic colorectal c
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning LYEL.
